Abstract

This invention relates to pharmaceutical formulations comprising triethylenetetramine tetrahydrochloride (TETA.4HCl). Specifically, it relates to pharmaceutical compositions which are suitable for once a day administration to a subject in need of treatment.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/132 - Amines, e.g. amantadine having two or more amino groups, e.g. spermidine, putrescine
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

This invention relates to pharmaceutical formulations comprising triethylenetetramine tetrahydrochloride (TETA·4HCl). Specifically, it relates to pharmaceutical compositions which are suitable for once a day administration to a subject in need of treatment.

IPC Classes  ?

• A61K 31/132 - Amines, e.g. amantadine having two or more amino groups, e.g. spermidine, putrescine
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets

Abstract

−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.

IPC Classes  ?

• C07C 211/14 - Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
• C07C 209/84 - Purification
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1° 2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.

IPC Classes  ?

• C07C 211/14 - Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C07C 209/84 - Purification

Abstract

−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.

IPC Classes  ?

• C07C 211/14 - Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
• C07C 209/84 - Purification
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to the treatment and/or monitoring of subjects suffering from, or susceptible to, Wilson's Disease, and involves measuring the serum non-ceruloplasmin (NCC) level in a subject and determining whether the serum NCC level is within a specified range. Treatment regimes can be adjusted if appropriate to control the subject's serum NCC level to be within the desired range.

IPC Classes  ?

• A61K 31/132 - Amines, e.g. amantadine having two or more amino groups, e.g. spermidine, putrescine
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61P 3/12 - Drugs for disorders of the metabolism for electrolyte homeostasis
• G01N 30/02 - Column chromatography
• G01N 30/72 - Mass spectrometers
• G01N 33/84 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving inorganic compounds or pH
• H01J 49/10 - Ion sourcesIon guns

Abstract

−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.

IPC Classes  ?

• C07C 211/14 - Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
• C07C 209/84 - Purification
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to the treatment and/or monitoring of subjects suffering from, or susceptible to, Wilson's Disease, and involves measuring the serum non-ceruloplasmin (NCC) level in a subject and determining whether the serum NCC level is within a specified range. Treatment regimes can be adjusted if appropriate to control the subject's serum NCC level to be within the desired range.

IPC Classes  ?

• A61K 31/132 - Amines, e.g. amantadine having two or more amino groups, e.g. spermidine, putrescine
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61P 39/04 - Chelating agents
• G01N 30/02 - Column chromatography
• G01N 30/72 - Mass spectrometers
• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis

Abstract

−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.

IPC Classes  ?

• C07C 211/14 - Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
• C07C 209/84 - Purification
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.

IPC Classes  ?

• C07C 211/14 - Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
• C07C 209/84 - Purification
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.

IPC Classes  ?

• C07C 211/14 - Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
• C07C 209/84 - Purification
• A61K 9/00 - Medicinal preparations characterised by special physical form